Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Regeneron Pharmaceuticals

CUSIP: 75886F957 | 34 institutional holders

Quarters

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Compare Detailed Historical Funds Options 13D/13G Peers Targeting Trading Summary Profile